Effects of cyclosporine or FK506 in chronic colitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 1075-1084

  Aiko, Satoshi ^a   Conner, Elaine M ^a   Fuseler, John A ^a   Grisham, Matthew B ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYELOPEROXIDASE; NITRATE; NITRIC OXIDE; NITRITE; PEPTIDOGLYCAN POLYSACCHARIDE; TACROLIMUS;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CHRONIC GRANULOMATOUS DISEASE; CHRONIC INFLAMMATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA PERMEABILITY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER GRANULOMA; LIVER WEIGHT; LYMPHOCYTE ACTIVATION; NONHUMAN; PERITONEUM ADHESION; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; COLITIS; COLON; CYCLOSPORINE; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; INTESTINAL MUCOSA; LIVER; NITRATES; NITRITES; ORGAN SIZE; PEPTIDOGLYCAN; POLYSACCHARIDES; RATS; RATS, INBRED LEW; SPLEEN; TACROLIMUS;

EID: 0030942498     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. AMON, A. U.: Cyclosporin A inhibits histamine release from human peripheral basophils and human skin mast cells. Agents Actions 36: Suppl. C, C250-C252, 1992.
2. BESARAB, A., JARRELL, B. E., HIRSCH, S., CARABASI, A., CHESSMAN, M. D. AND GREEN, P.: Use of the isolated perfused kidney model to assess the acute pharmacologie effects of cyclosporine and its vehicle, cremophor EL. Transplantation 44: 195-201, 1987.
3. BICKEL, M., TSUDA, H., AMSTAD, P. EVEQUOZ, V., MERGENHAGEN, S. E., WAHL, S. M. AND PLUNKIT, D. H.: Differential regulation of colony-stimulating factors and interleukin 2 production by cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 84: 3274-3277, 1987.
4. BLACKHAM, A. AND GRIFFITHS, R. J.: The effect of FK506 and cyclosporin A on antigen-induced arthritis. Clin. Exp. Immunol. 86: 224-228, 1991.
5. BRUNKWALL, J. AND BERGQVIST, D.: The effect of cyclosporine A dissolved in chremofore or in ethanol and of cortisone on the arterial release of prostacyclin. J. Surg. Res. 05: 622-627, 1993.
6. CONDE, M., ANDRADE, J., BEDOYA, F. J., SANTA MARIA, C. AND SOBRINO, F.: Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology 84: 476-481, 1995.
7. DAWSON, T. M., STEINER, J. P., DAWSON, V. L., DINERMAN, J. L., UHL, G. R. AND SNYDER, S. H.: Immunosuppressant FK 506 enhances phosphorylation of nitric oxide synthetase and protects against glutamate neurotoxicity, Proc. Natl. Acad. Sci. U.S.A. 90: 9808-9812, 1993.
8. FAULDS, D., GOA, K. L. AND BENFIELD, P.: Cyclosporin. A Review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040, 1993.
9. FURMAN, D. A., KLEE, C. B., BIERER, B. E. AND BURAKOFF, S. J.: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 89: 3686-3690, 1992.
10. GRISHAM, M. B., DEMICHELE, S. J. AND GARLIEB, K. A.: Effects of sulfasalazine or enteral diets containing either fish oil or oligosaccharides on mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Inflammatory Bowel Dis. 2: 178-188, 1996.
11. GRISHAM, M. B., JOHNSON, G. G., GAUTREAUX, M. D. AND BERG, R. D.: Measurement of nitrate and nitrite in extracellular fluids: A window to systemic nitric oxide metabolism. Methods Disease 7: 84-90, 1995.
12. GRISHAM, M. B., SPECIAN, R. D. AND ZIMMERMAN, T. E.: Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis: J. Pharmacol. Exp. Ther. 271: 1114-1121, 1994.
13. HARDING, M. W., GALAT, A., UELING, D. E. AND SCHREIBER, S. L.: A receptor for the immunosuppressant FK506 ia a cic-trans peptidylpropylisomerase. Nature 341: 758-760, 1989.
14. HATFIELD, S. M., MYNDERSE, J. S. AND ROEHM, N. W.: Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. J. Pharmacol. 261: 970-976, 1992.
15. HIGA, A., MCKNIGHT, G. W. AND WALLACE, J. L.: Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur. J. Pharmacol. 239: 171-176, 1993.
16. KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M. AND AOKI, H.: FK-506, a novel immunosuppressant isolated from streptomyces: II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 40: 1256-1265, 1987.
17. KLASEN, I. S., MELIEF, M. J., VAN HALTEREN, A. G. S., SCHOUTEN, W. R., VAN BLANKENSTEIN, M., HOKE, G., DE VISSER, H., HOOIJKAAS, H. AND HAZENBERG, M. P.: The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease. Clin. Immunol. Immunopathol. 71: 303-308, 1994.
18. KOLB, G., ECKLE, I., BITTNER, K., MHLLER, T., HAVEMANN, K. AND LANGE, H.: Latent inhibition of granulocyte function by cyclosporine A. Immunobiology 181: 22-30, 1990.
19. KUBES, P., HUNTER, J. AND GRANGER, N.: Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat. Dig. Dis. Sci. 36: 1469-1472, 1991.
20. LICHTIGER, S., PRESENT, D. H., KORNBLUTH, A., GELERNT, I., BAUER, J., GALLER, G., MICHELASSI, F. AND HANAUER, S.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330: 1841-1845, 1994.
21. MARUMO, T., NAKAKI, T., HISHIKAWA, K., SUZUKI, H., KATO, R. AND SARUTA, T.: Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 25: 764-768, 1995.
22. MORRIS, R. E.: Mechanisms of action of new immunosuppressive drugs. Ther. Drug Monit. 17: 564-569, 1995.
23. OCHIAI, T., NAGATA, M., NAKAJIMA, K., SAKAMOTO, K., ASANO, T. AND ISONO, K.: Prolongation of canine renal allograft survival by treatment with FK-506. Transplant. Proc. 19: Suppl. 6, 53-56, 1987.
24. OHARA, K., BILLINGTON, R., JAMES, R. W., DEAN, G. A., NISHIYAMA, M. AND NOGUCHI, H.: Toxicological evaluation of FK506. Transplant. Proc. 22: Suppl. 1, 83-88, 1990.
25. PIGATTO, P. D., MOZZANICA, N., POLENGHI, M. M., AITOMARE, G. F. AND FlNZI, A. F.: Cyclosporine A inhibits polymorphonuclear leukocyte chemotaxis in vivo. Transplant. Proc. 20: Suppl. 4, 91-94, 1988.
26. SANDBORN, W. J. AND TREMAINE, W. J.: Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. 67: 981-990, 1992.
27. SARTOR, R. B.: Cyclosporine therapy for inflammatory bowel disease. N. Engl. J. Med. 330: 1897-1898, 1994.
28. SUZUKI, S., TOLEDO-PEREYRA, H., RODRIGUEZ, F. J. AND CEJALVO, D.: Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Transplantation 55: 1265-1272, 1993.
29. TOCCI M. J., MAKTOVICH D. A., COLLIER K. A., KWOK, P., DUMONT, F., LIN, S., DEGUDICIBUS, S., SIEKIERKA, J. J., CHIN, J. AND HUTCHINSON, N. I.: The immu- nosuppressant FK 506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143: 718-726, 1989.
30. VON RITTER, C., SEKIZUKA, E., GRISHAM, M. B. AND GRANGER, D. N.: The chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine increases mucosal permeability in the distal ileum of the rats. Gastroenterology 95: 651-656, 1988.
31. WALLACE, J. L., HOGABOAM, C. M. AND KUBES, P.: Immunopathology of NSAID-gastropathy: inhibitory effects of interleukin-I and cyclosporin A. Ann. NY Acad. Sci. 664: 400-407, 1992.
32. WENZEL-SEIFERT, K, AND SEIFERT, R.: Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. Naunyn-Schmiedebergs Arch. Pharmacol. 348: 7-13, 1993.
33. YAMADA, T., SARTOR, R, B., MARSHALL, S., SPECIAN, R. D. AND GRISHAM, M. B.: Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology 104: 759-711, 1993.